Skip to main content
ZNTL
NASDAQ Life Sciences

10% Owner Walters Group Makes $7.75M Open Market Purchase in Zentalis Pharmaceuticals

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$2.82
Mkt Cap
$205.192M
52W Low
$1.01
52W High
$3.19
52W Position info
179% above low
Off High info
12% below high
Rel. Volume info
6.9× avg
Market data snapshot near publication time

ZNTL has more than doubled off its 52-week low of $1.01 on elevated volume (6.9× avg).

Summary

The Walters Group, a 10% owner of Zentalis Pharmaceuticals, reported a significant open market purchase of common stock totaling over $7.75 million. This transaction increases their stake and signals strong conviction in the company.


Key Events · Ownership and Investor Activity · ZNTL

  • Significant Insider Purchase

    The Walters Group, a 10% owner, acquired 6,459,973 shares of Zentalis Pharmaceuticals common stock through an open market purchase.

  • Substantial Investment Value

    The total value of the purchase was $7,751,968, executed at a price of $1.20 per share on December 31, 2025.

  • Increased Ownership Stake

    Following this transaction, the Walters Group's direct holdings in Zentalis Pharmaceuticals increased to 13,509,973 shares.


Analysis · ZNTL · Life Sciences

This substantial open market purchase by a 10% owner is a strong positive signal. The Walters Group, comprising William T. Walters and Susan B. Walters, significantly increased their stake, demonstrating high conviction in Zentalis Pharmaceuticals. Such a large investment from a major shareholder often suggests confidence in the company's future prospects and valuation. Investors may view this as a bullish indicator, potentially signaling an undervaluation or upcoming positive developments.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ZNTL was trading at $2.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $205.2M. The 52-week trading range was $1.01 to $3.19. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ZNTL - Latest Insights

ZNTL
Nov 09, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.74
Real-time Price: $1.38 info
Change: -$0.360 (-21%) info
Market Cap: $133.642M info
ZNTL
Oct 23, 2026, 10:15 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.31
Real-time Price: $1.38 info
Change: -$0.930 (-40%) info
Market Cap: $133.642M info
ZNTL
Oct 19, 2026, 2:31 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $2.29
Real-time Price: $1.38 info
Change: -$0.905 (-40%) info
Market Cap: $133.642M info
ZNTL
Oct 18, 2026, 6:11 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $2.11
Real-time Price: $1.38 info
Change: -$0.730 (-35%) info
Market Cap: $133.642M info
ZNTL
Aug 19, 2026, 6:11 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $3.82
Real-time Price: $1.38 info
Change: -$2.44 (-64%) info
Market Cap: $133.642M info